Disease detection methodologies in relapsed B‐cell acute lymphoblastic leukemia: Opportunities for improvement. Issue 4 (25th January 2020)

• Record Type: Journal Article
• Authors: Shalabi, Haneen; Yuan, Constance M.; Kulshreshtha, Amita; Dulau‐Florea, Alina; Salem, Dalia; Gupta, Gaurav K.; Roth, Mark; Filie, Armando C.; Yates, Bonnie; Delbrook, Cindy; Derdak, Joanne; Mackall, Crystal L.; Lee, Daniel W.; Fry, Terry J.; Wayne, Alan S.; Stetler‐Stevenson, Maryalice; Shah, Nirali N.
• Is Part Of: Pediatric blood & cancer. Volume 67:Issue 4(2020)
• Page Start: n/a
• Page End: n/a
• Publication Date: 2020-01-25
• Subjects: acute lymphoblastic leukemia -- CSF -- minimal residual disease; Tumors in children -- Periodicals; Blood -- Diseases -- Periodicals; Cancer in children -- Periodicals; 618.92
• DOI: 10.1002/pbc.28149
• Languages: English
• ISSNs: 1545-5009

Abstract

Abstract: Background: Accurate disease detection is integral to risk stratification in B‐cell acute lymphoblastic leukemia (ALL). The gold standard used to evaluate response in the United States includes morphologic evaluation and minimal residual disease (MRD) testing of aspirated bone marrow (BM) by flow cytometry (FC). This MRD assessment is usually made on a single aspirate sample that is subject to variability in collection techniques and sampling error. Additionally, central nervous system (CNS) assessments for ALL include evaluations of cytopathology and cell counts, which can miss subclinical involvement. Procedure: We retrospectively compared BM biopsy, aspirate, and FC samples obtained from children and young adults with relapsed/refractory ALL to identify the frequency and degree of disease discrepancies in this population. We also compared CNS FC and cytopathology techniques. Results: Sixty of 410 (14.6%) BM samples had discrepant results, 41 (10%) of which were clinically relevant as they resulted in a change in the assignment of marrow status. Discrepant BM results were found in 28 of 89 (31.5%) patients evaluated. Additionally, cerebrospinal fluid (CSF) FC identified disease in 9.7% of cases where cytopathology was negative. Conclusions: These results support further investigation of the role of concurrent BM biopsy, with aspirate and FC evaluations, and the addition of FC to CSF evaluations, to fully assess disease status and response, particularly in patients with relapsed/refractory ALL. Prospective studies incorporating more comprehensive analysis to evaluate the impact on clinical outcomes are warranted.